SCHEMBL30890738

SCHEMBL30890738

CC(C)C[C@@H](C(=O)N1CC2(C[C@H]1C(N)=O)Oc1ccccc1NC2=O)N(C)C(=O)c1cc2c(F)cc(F)cc2[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27245023 0.91 GHSR (0.30) —
SCHEMBL27245017 0.91 GHSR (0.30) —
SCHEMBL30890689 0.90 OTUD7B (0.30) —
SCHEMBL27244669 0.89 — —
SCHEMBL27244673 0.89 — —
SCHEMBL30890564 0.88 PLD2 (0.34) —
SCHEMBL29655530 0.86 — —
SCHEMBL27245190 0.82 MAPT (0.32) —
SCHEMBL27245200 0.82 MAPT (0.32) —
SCHEMBL24448339 0.81 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4612156-A1 ANTI-VIRAL COMPOUNDS Aligos Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
WO-2024097296-A1 ANTI-VIRAL COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2024-05-10 — — WO disclosed
Send feedback